{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/ATX.AU"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ATX.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ATX.AU\",,,,,undefined,":{"symbol":"ATX.AU","market":"AU","secType":"STK","nameCN":"AMPLIA THERAPEUTICS LTD","latestPrice":0.054,"timestamp":1745887050942,"preClose":0.054,"halted":0,"volume":228625,"delay":0,"nameEN":"AMPLIA THERAPEUTICS LTD","floatShares":267814706,"shares":387952669,"eps":-0.027671,"marketStatus":"Trading","change":0,"latestTime":"04-29 13:44:38 AEST","open":0.054,"high":0.055,"low":0.054,"amount":12346,"amplitude":0.018519,"askPrice":0.054,"askSize":110000,"bidPrice":0.053,"bidSize":50000,"shortable":3,"etf":0,"ttmEps":-0.027671,"tradingStatus":2,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1745906400000},"marketStatusCode":2,"adr":0,"exchange":"ASX","adjPreClose":0.054,"openAndCloseTimeList":[[1745884800000,1745906400000]],"volumeRatio":2.695247,"lotSize":1,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ATX.AU\",,,,,undefined,":{"symbol":"ATX.AU","floatShares":267814706,"roa":"-24.61%","roe":"-44.96%","lyrEps":-0.023212,"volumeRatio":2.695247,"shares":387952669,"dividePrice":0,"high":0.055,"amplitude":0.018519,"preClose":0.054,"low":0.054,"week52Low":0.049,"pbRate":"1.64","psRate":"6.14","week52High":0.18,"institutionHeld":0,"latestPrice":0.054,"committee":-0.375,"eps":-0.027671,"divideRate":0,"volume":228625,"delay":0,"ttmEps":-0.027671,"open":0.054,"prevYearClose":0.089,"prevWeekClose":0.051,"prevMonthClose":0.07,"prevQuarterClose":0.07,"fiveDayClose":0.052,"twentyDayClose":0.072,"sixtyDayClose":0.081},"@#url:\"https://hq.skytigris.cn/market/plate/belongs/ATX.AU\",params:#limit:6,delay:false,,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ATX.AU\",pageSize:4,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2526826808","title":"Amplia Therapeutics Says Initiation Activities for US Pancreatic Cancer Trial Underway","url":"https://stock-news.laohu8.com/highlight/detail?id=2526826808","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526826808?lang=en_us&edition=fundamental","pubTime":"2025-04-09 10:35","pubTimestamp":1744166123,"startTime":"0","endTime":"0","summary":"Amplia Therapeutics  said initiation activities for its pancreatic cancer trial in the US have started, focusing on the combination of the company's focal adhesion kinase inhibitor narmafotinib with chemotherapy Folfirinox for advanced pancreatic cancer patients, according to a Wednesday filing with the Australian bourse.The company partnered with a contract research organization to manage clinical trial activities in the US, the filing said.The trial will be run under the investigational new drug application for narmafotinib which was cleared by the US Food and Drug Administration, per the filing.Shares rose nearly 2% in recent trade Wednesday.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7067","BK4139","LENZ","ATX.AU","BK4007"],"gpt_icon":0},{"id":"2526355062","title":"Insider Purchases Worth AU$949.9k See Losses As Amplia Therapeutics Market Value Drops To AU$21m","url":"https://stock-news.laohu8.com/highlight/detail?id=2526355062","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526355062?lang=en_us&edition=fundamental","pubTime":"2025-04-09 08:12","pubTimestamp":1744157571,"startTime":"0","endTime":"0","summary":"Insiders who bought AU$949.9k worth of Amplia Therapeutics Limited's ( ASX:ATX ) stock at an average buy price of...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-atx/amplia-therapeutics-shares/news/insider-purchases-worth-au9499k-see-losses-as-amplia-therape","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LENZ","ATX.AU","BK4139","BK7067","BK4007"],"gpt_icon":0},{"id":"2522336837","title":"ASX Small-Cap Stocks to Watch","url":"https://stock-news.laohu8.com/highlight/detail?id=2522336837","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522336837?lang=en_us&edition=fundamental","pubTime":"2025-03-27 07:42","pubTimestamp":1743032577,"startTime":"0","endTime":"0","summary":"Investors are likely to keep an eye on the following small-cap stocks listed on the Australian Securities Exchange.Amplia Therapeutics Amplia Therapeutics said data from its phase 2a clinical trial showed \"promising efficacy and good tolerability.\" The trial is investigating the use of its focal adhesion kinase inhibitor narmafotinib in combination with standard chemotherapy for advanced pancreatic cancer treatment.Recharge Minerals Recharge Minerals started the permitting process for exploration drilling at the Carter project in Montana, working with a consulting group to ensure environmental and land use compliance for future drill programs.Raiden Resources Raiden Resources began second-phase drilling on the Vuzel project in Bulgaria, aiming to assess the area's potential to host a near-surface gold deposit.Desert Metals Desert Metals started an 86-hole, 3,500-meter air core drilling program at the Tengrela South gold permit in the Ivory Coast, aiming to test the weathered oxide laye","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["XJO.AU","ATX.AU","BK7067","XKO.AU","SCN.AU","BK7095","RDN.AU","DM1.AU","REC.AU","XAO.AU"],"gpt_icon":0},{"id":"2516752495","title":"Amplia Therapeutics Gets US FDA Nod for Changes to Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2516752495","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516752495?lang=en_us&edition=fundamental","pubTime":"2025-03-03 11:52","pubTimestamp":1740973936,"startTime":"0","endTime":"0","summary":"Amplia Therapeutics  said the US Food and Drug Administration said that its proposed changes to a study of FAK inhibitor narmafotinib, in combination with the chemotherapy regime FOLFIRINOX, in advanced pancreatic cancer patients \"appear reasonable,\" according to a Monday Australian bourse filing.The firm sought feedback from the regulator regarding the proposed changes, including those related to the dose-escalation and dose-optimization phase of the study and concerning the removal of a pharmacokinetic assessment of FOLFIRINOX in the trial.The nod will allow the firm to finalize the study protocol and initiate the final stages of trial planning.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","BK7067","ATX.AU","LENZ"],"gpt_icon":0}],"pageSize":4,"totalPage":4,"pageCount":1,"totalSize":14,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ATX.AU\",params:#limit:5,,,undefined,":[{"market":"AU","date":"2024-04-18","symbol":"ATX.AU","defaultRemindTime":1713398400000,"type":"split","dateTimestamp":1713362400000,"forFactor":971896,"toFactor":1000000,"ratio":0.971896}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ATX.AU\",market:\"AU\",,,undefined,":[]}}